
OAC-ALONE #TCT2018



Trial description: Patients with stable CAD with PCI >1 year ago and AF on oral anticoagulation (OAC) were randomized to either OAC + single antiplatelet therapy (SAPT) or OAC alone. Patients were followed for 2.5 years.



RESULTS

- Trial was terminated early. Primary endpoint, all-cause mortality, MI, stroke, systemic embolism: OAC + SAPT vs. OAC: 13.6% vs. 15.7%, $p_{noninferiority} = 0.20$, $p_{superiority} = 0.45$
- Stent thrombosis: 0% vs. 0.6%, p = 0.15; stroke/systemic embolism: 5.5% vs. 3.8%, p = 0.29; ISTH major bleed: 10.4% vs. 7.8%, p = 0.22

CONCLUSIONS

- Due to premature cessation of the trial, noninferiority of OAC alone could not be established compared with OAC + SAPT among patients with AF and stable CAD with remote PCI
- MI rates were extremely low overall (1-2% over 2.5 years)

Matsumura-Nakano Y, et al. Circulation 2018;Sep 24:[Epub]